Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 14, 2005. The report serves as a notification of changes in director interests rather than a comprehensive financial statement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on specific share transactions by a director.
Material Changes
The material change reported involves the shareholding of Mr. A.P. Witty, a person discharging managerial responsibility:
- Option Exercise: On November 8, 2005, Mr. Witty exercised options over 11,744 Ordinary shares granted on August 14, 1996, at a price of GBP 8.94 per share.
- Share Sale: On November 8, 2005, Mr. Witty sold 6,903 Ordinary shares at a price of GBP 15.26 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The report is a compliance notification under Disclosure Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the net change in Mr. Witty's shareholding following the exercise and subsequent sale.
- Confirm the pricing details of the option exercise (GBP 8.94) versus the market sale price (GBP 15.26).
- Note that this filing does not contain updated financial performance data for the company.